Wilkinson: What is the Deal with Esketamine?
Samuel Wilkinson, MD, Assistant Professor of Psychiatry and Assistant Director of the Yale Depression Research Program, writes in Psychiatric Times about the drug esketamine, approved by the U.S. Food and Drug Administration last year as the first rapid-acting therapy for treatment-resistant depression.
Wilkinson Honored with New Investigator Award from ISCTM
Samuel Wilkinson, MD, Assistant Professor of Psychiatry and Assistant Director of the Yale Depression Research Program, has been awarded a New Investigator Award from the International Society of CNS Clinical Trials and Methodology (ISCTM).
New depression drug related to ketamine recommended by FDA panel
Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry; Director of the Yale Depression Research Program; and Co-Director of the Yale New Haven Hospital Interventional Psychiatry Service is featured in a NBC Nightly News report about the drug esketamine.
Acute and longer-term outcomes using ketamine as a clinical treatment at the Yale Psychiatric Hospital
Yale researchers, including first author Samuel Wilkinson, MD, Assistant Professor of Psychiatry, describe in a paper published in Biological Psychiatry their experience providing ketamine as a clinical treatment to participants with severe and treatment-resistant mood disorders.
Depression treatments inspired by ketamine move ahead in tests
Antidepressant drugs that work in hours instead of weeks could be on the market within three years, researchers say. "I think it's highly probable that we'll see some version of one of these treatments being approved in the relatively near future," says Dr. Gerard Sanacora, director of the Yale Depression Research Program.
Suicide prevention and ketamine
Suicide, a significant public health problem, is closely linked with mental health conditions, especially depression. At the Yale Depression Research Clinic, a clinical trial is now underway to determine whether esketamine, a form of the drug ketamine, can help prevent suicide in depressed patients.
New drug shows same antidepressant effect as ketamine, study shows
A drug under development seems to have similar antidepressant effects as previously observed with ketamine, but without the same level of dangerous side effects seen when the anesthetic is abused as a party drug, according to a new Yale-led study. Gerard Sanacora, MD, PhD, professor of psychiatry and director of the Yale Depression Research Program, is first author.
Further Guidance for Researchers
In follow-up to recent communications from President Salovey, Provost Strobel, and me, basic science chairs and directors convened today to discuss the meaning of critical or essential work in the laboratory setting. As the situation on-the-ground around COVID evolves, so must our definition of critical and essential functions in the laboratory.
Researchers Find Correlation Between Pain and Overeating in Veterans
Over 40 percent of veterans screened by Yale researchers overate in response to physical pain at least once in the 30 days prior to being surveyed, a new study shows. The lead author of the study was Robin Masheb, PhD, Senior Research Scientist in Psychiatry at Yale School of Medicine.
Antidote to Pain and Negativity? Let It Be.
Hedy Kober, PhD, Associate Professor of Psychiatry and Psychology, is the corresponding author of a paper published in Social, Cognitive, and Affective Neuroscience that touts the benefits of mindfulness to help people deal with physical pain and negative emotions.
In the right (lab) culture, mentorship flourishes — and science benefits
You might imagine a science lab looking a bit sterile and impersonal — little sunlight, masked figures in white coats pouring neon-colored liquid into beakers, all business. You might not expect to hear a science lab referred to as familial, where badminton tournaments, movie nights and barbeques are commonplace.
Trainee-Led Study Seeks to Better Understand All-Cause Mortality in Schizophrenia Patients
A new study led by a Yale Department of Psychiatry trainee sought to better understand why people with schizophrenia have dramatically increased all-cause mortality, and whether living with severe mental illness accelerates the aging process.